Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacological approaches.

Pedro C Avila1, Jeffrey L Kishiyama, Daniel C Adelman

  • 1University of California at San Francisco, San Francisco, California, USA.

Clinical Allergy and Immunology
|October 2, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Barriers and Solutions to Optimal Food Allergy Prevention, Diagnostic, and Management Strategies.

The journal of allergy and clinical immunology. In practice·2025
Same author

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.

Allergy·2024
Same author

5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function.

Frontiers in allergy·2024
Same author

Patient-reported outcome measures for urticaria and angioedema.

The Journal of allergy and clinical immunology·2023
Same author

Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.

The Journal of allergy and clinical immunology·2023
Same author

Is It Time to Supplement Vitamin D and Fish Oil Prenatally to Prevent Offspring Croup?

The journal of allergy and clinical immunology. In practice·2023
Same journal

Information and consent forms for sublingual immunotherapy.

Clinical allergy and immunology·2008
Same journal

Instructions and consent forms for subcutaneous allergen immunotherapy.

Clinical allergy and immunology·2008
Same journal

Prevention and treatment of anaphylaxis.

Clinical allergy and immunology·2008
Same journal

Adverse effects associated with sublingual immunotherapy.

Clinical allergy and immunology·2008
Same journal

Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.

Clinical allergy and immunology·2008
Same journal

Unproven and controversial forms of immunotherapy.

Clinical allergy and immunology·2008
See all related articles

Treating atopic diseases often requires multiple drugs due to complex allergic inflammation. Research suggests blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) may reduce airway allergic inflammation.

Area of Science:

  • Immunology
  • Allergy Research
  • Pharmacology

Background:

  • Atopic diseases like asthma and dermatitis involve complex allergic inflammation.
  • Current treatments may not be uniformly effective across all atopic disorders.
  • Th2 inflammation plays a central role in various atopic conditions.

Purpose of the Study:

  • To explore novel therapeutic targets for atopic diseases.
  • To investigate the role of specific cytokines in allergic inflammation.
  • To identify potential strategies for improving treatment efficacy.

Main Methods:

  • Review of existing research on atopic disease treatment.
  • Analysis of the role of Th2 inflammation and associated cytokines.
  • Examination of animal studies on cytokine blockade.

Related Experiment Videos

Main Results:

  • Antihistamines are effective for allergic rhinitis but not asthma.
  • Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are key cytokines in airway allergic inflammation.
  • Blocking IL-4 and IL-13 shows promise in reducing allergic inflammation.

Conclusions:

  • Multidrug regimens are often necessary for moderate to severe atopic diseases.
  • Targeting critical immunopathological junctures, like IL-4 and IL-13, is a promising therapeutic avenue.
  • Further research into cytokine-specific therapies could lead to more effective treatments for atopic disorders.